triple antagonist glp-1 Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature LY3437943, a novel triple glucagon,

5.4 Pharmacological effects of SIN in other diseases SIN has exhibited therapeutic efficacy in various diseases, including colitis (119), atherosclerosis (120), myocardial ischemiareperfusion injury (100), chronic sciatic nerve injury (CCI) (121), renal injury (122), colorectal cancer (123), lung cancer, liver cancer, cervical cancer, bladder cancer, gastric cancer, and renal cancer (93, 124, 125)

49 Model adjustment and rebuilding were performed in COOT

J Appl Anim Res

Consistent use of GLP medications leads to common side effects and lowers your energy levels

Adding a medication like Jardiance to Ozempic therapy could provide additional cardiovascular benefits, particularly in those with heart failure or a high risk of cardiovascular disease

NOTES None Acknowledgements Fig